Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut 1 stage IV NSCLC: phase 1b safety results

被引：0
|
作者：
Nakagawa, K. [1 ]
Garon, E. B. [2 ]
Paz-Ares, L. [3 ]
Ponce, S. [3 ]
Corral Jaime, J. [4 ]
Juan Vidal, O. [5 ]
Nadal, E. [6 ]
Kiura, K. [7 ]
He, S. [8 ]
Treat, J. [8 ]
Dalal, R. [9 ]
Lee, P. [9 ]
Reck, M. [10 ]
Novello, S. [11 ]
机构：
[1] Kinki Univ, Sch Med, Osaka, Japan
[2] UCLA Med Ctr, Santa Monica, CA USA
[3] Hosp Doce Octubre, Madrid, Spain
[4] Hosp Virgen del Rocio, Seville, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Inst Catala Oncol, Barcelona, Spain
[7] Okayama Univ Hosp, Kita Ku, Okayama, Japan
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Bridgewater, MA USA
[10] German Ctr Lung Res DZL, ARCN, Lungen Clin Grosshansdorf, Grosshansdorf, Germany
[11] Eli Lilly Italia SpA, Sesto Fiorentino, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E6
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
    Overcash, J. Scott
    Bhiwandi, Pouru
    Garrity-Ryan, Lynne
    Steenbergen, Judith
    Bai, Stephen
    Chitra, Surya
    Manley, Amy
    Tzanis, Evan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [42] A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS)
    Cote, Gregory Michael
    Choy, Edwin
    Thornton, Katherine Anne
    Mazzola, Emanuele
    Bouberhan, Sara
    Merriam, Priscilla
    Wagner, Andrew J.
    Morgan, Jeffrey A.
    Haddox, Candace L.
    Oza, Jay
    Demetri, George D.
    George, Suzanne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin J.
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Alexanian, Raymond
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Parmar, Simrit
    Shah, Nina
    Popat, Uday R.
    Orlowski, Robert Z.
    [J]. BLOOD, 2012, 120 (21)
  • [44] A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)
    Dai, Guang-Hai
    Jia, Ru
    Si, Haiyan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Zhang, Bei
    Tong, Shuang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Phase 1b study of aldoxorubicin plus gemcitabine in metastatic solid tumors.
    Sankhala, Kamalesh Kumar
    Chawla, Shanta
    Chua, Victoria S.
    Sachdev, Jasgit C.
    Borazanci, Erkut Hasan
    Sung, Kelli
    Mita, Monica M.
    Mita, Alain C.
    Laabs, Brenda
    Wieland, Scott
    Levitt, Daniell.
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC
    Camidge, Ross
    Cappuzzo, Federico
    Go, Jowell
    Isaacson, Jeffrey
    Litten, Jason
    Park, Keunchil
    Spigel, David R.
    Spira, Alexander
    Vergnenegre, Alain
    Wolf, Juergen
    Yang, James Chih-Hsin
    Mok, Tony
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S427
  • [47] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Ou, Xiaoling
    Walding, Andrew
    Dymond, Angela W.
    Ren, Song
    Cantarini, Mireille
    Janne, Pasi A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723
  • [48] CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
    Shu, Catherine A.
    Goto, Koichi
    Cho, Byoung Chul
    Griesinger, Frank
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Xie, John
    Chen, Jun
    Mahoney, Janine
    Thayu, Meena
    Knoblauch, Roland Elmar
    Trani, Leonardo
    Bauml, Joshua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
    Uy, Geoffrey L.
    Pullarkat, Vinod A.
    Baratam, Praneeth
    Stuart, Robert K.
    Faderl, Stefan
    Chandrasekaran, Vijayalakshmi
    Wang, Qi
    Chakravarthy, Divya
    Cheung, Ronald S.
    Lin, Tara L.
    [J]. BLOOD, 2021, 138
  • [50] A Phase 1b/2 Study of the Safety and Tolerability of Tinlarebant in Adolescent STGD1 Subjects
    Grigg, John R.
    Chen, Fred Kuanfu
    Chen, Ta-Ching
    Jamieson, Robyn V.
    Mata, Nathan L.
    Liao, Webber
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
12345